Moringa Acquisition Corp Shareholders Approve Silexion Merger

Published 13/08/2024, 00:00
Moringa Acquisition Corp Shareholders Approve Silexion Merger

New York-based special purpose acquisition company Moringa Acquisition Corp (NASDAQ:MACA) announced today that its shareholders have given the green light to the proposed business combination with Silexion Therapeutics Ltd., an Israeli biotech firm. The approval occurred during an extraordinary general meeting held on Monday.

The meeting, which took place on August 6, 2024, saw shareholders cast their votes on several critical proposals related to the merger. The Business Combination Agreement, initially set on April 3, 2024, was ratified with a significant majority, receiving 92.2% of the votes in favor, with 3,567,465 votes for and 5,285 against. This agreement paves the way for Moringa to proceed with the merger under the terms outlined in the document.

Additionally, shareholders approved two special resolutions under Cayman Islands law. The first, known as the Merger Proposal, was passed with the same margin as the Business Combination Proposal. This resolution will see Moringa become a wholly-owned subsidiary of Biomotion Sciences, as Merger Sub 2 merges into Moringa, and the company's memorandum and articles of association are amended to reflect the status of a privately-owned company.

The second special resolution, the Articles Amendment Proposal, was approved by an even larger margin, with 92.3% in favor, amounting to 3,572,750 votes for and none against. This amendment will eliminate the requirement that New Pubco maintain a minimum of $5,000,001 in net tangible assets after subtracting the transaction expenses and liabilities due at the closing of the business combination with Silexion.

The fourth proposal on the agenda, which would have adjourned the meeting if necessary, was not voted upon as the prior proposals were approved without issue.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.